FrancophonIA/ELRC3.0 huggingface dataset:
English: People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Maltese: Nies li huma sensittivi għal mediċini mhux sterojdi kontra l-infjammazzjoni (NSAIDs) għandhom jevitaw li jmissu mal-prodott mediċinali veterinarju.
English: Pharmacotherapeutic group: Musculo-skeletal system, antiinflammatory and antirheumatic products, non-steroids.
Maltese: Prodotti tas-sistema muskoloskeletali anti-infjammatorji u anti rewmatiċi, mhux sterojdi
English: QUANTITY OF THE ACTIVE SUBSTANCE(S)
Maltese: TAS-SUSTANZA(i)ATTIVA(I)
English: Polyethylene bottle containing 5 ml, 10 ml or 25 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.
Maltese: Flixkun tal-polypropylene li fih 5ml, 10 ml jew 25 ml b'tapp li jirreżisti l-ftuħ mit-tfal żgħar u siringa tal-kejl tal-polypropylene.
English: HR-10436 Rakov Potok
Maltese: MILL-ĦRUĠ TAL-LOTT
English: Bottle of 10, 25 or 50 ml
Maltese: Flixkun ta' 10, 25 jew 50 ml
English: Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats.
Maltese: Serħan ta' wġigħ u infjammazzjoni f'mard muskolu-skeletriku kroniku fil-qtates.
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
Maltese: It-trattament għandu jitkompla darba kuljum bl-għoti orali (f'intervalli ta' 24 siegħa) bid-doża tal-manteniment ta' 0.05 mg ta' meloxicam / kg ta' piż tal-ġisem.
English: Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Maltese: Reazzjonijiet avversi tipiċi ta' mediċini mhux sterojdi kontra l-infjammazzjoni (NSAIDs) bħal nuqqas t'aptit, rimettar, dijarea, demm moħbi fl-ippurgar, apatija u insuffiċjenza renali kienu rrappurtati xi kultant.
English: Meloxicam 0.5 mg.
Maltese: 0.5 mg
English: Meloxoral 0.5 mg/ml oral suspension for cats
Maltese: Meloxoral 0.5 mg/ml suspensjoni orali għall-qtates
English: Yellow/ green suspension.
Maltese: Suspensjoni safra/ħadranija.
English: Bottle of 5, 10 or 25 ml
Maltese: Flixkun ta' 5, 10 jew 25 ml
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Maltese: TAS-SUSTANZA(I) ATTIVA
English: Dosage
Maltese: Qtates
English: Water, purified
Maltese: Aroma tal-aniżetta Ilma, purifikat
English: Bottle of 125 or 180 ml
Maltese: Flixkun ta' 125 jew 180 ml
English: Bottles of 5, 10 or 25 ml.
Maltese: Flixken ta' 5, 10 jew 25 ml.
English: There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range.
Maltese: Hemm relazzjoni lineari bejn id-doża mogħtija u l-konċentrazzjoni fil-plażma osservata fil-firxa taddoża terapewtika.
English: Dogs
Maltese: Dożaġġ
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Maltese: It-trattament għandu jitkompla darba kuljum bl-għoti orali (f'intervalli ta' 24 siegħa) biddoża tal-manteniment ta' 0.1 mg meloxicam / kg ta' piż tal-ġisem.
English: Meloxoral 0.5 mg/ml oral suspension for cats Meloxicam
Maltese: VETERINARJU Meloxoral 0.5 mg/ml suspensjoni orali għall-qtates Meloxicam
English: In the case of overdose symptomatic treatment should be initiated.
Maltese: F'każ ta' doża eċċessiva, għandu jinbeda trattament sintomatiku.
English: THE NETHERLANDS
Maltese: L-OLANDA
English: Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Maltese: Reazzjonijiet avversi tipiċi ta' NSAIDs bħal nuqqas t'aptit, rimettar, dijarea, demm moħbi fl-ippurgar, apatija u insuffiċjenza renali kienu rrappurtati xi kultant.
English: Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Maltese: Madwar 75 % tad-doża mogħtija tiġi eliminata mal-ippurgar u l-bqija permezz tal-awrina.
English: PROHIBITION OF SALE, SUPPLY AND/OR USE
Maltese: Suspensjoni safra fl-aħdar
English: Meloxoral 1.5 mg/ml oral suspension for dogs meloxicam
Maltese: Meloxoral 1.5 mg/ml suspensjoni orali għall-klieb meloxicam
English: If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Maltese: Jekk iseħħu reazzjonijiet avversi, it-trattament għandu jitwaqqaf u wieħed għandu jfittex il-parir ta' veterinarju.
English: For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Meloxoral can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Maltese: Għal trattament iktar fit-tul, ġaladarba r-rispons kliniku jkun ġie osservat (wara ≥ 4 ijiem), id-doża ta' Meloxoral tista' tiġi aġġustata għall-inqas doża effettiva individwali, li tirrifletti li l-grad ta' uġigħ u ta' infjammazzjoni marbuta ma' mard kroniku muskolu-skeletriku, jista' jvarja matul iż-żmien.
English: Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Maltese: Evita l-użu fi kwalunkwe annimal li jkun deidratat, ipovolaemiku jew ipotensiv, għax hemm riskju potenzjali ta' żieda fit-tossiċità tal-kliewi.
English: Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Maltese: Madwar 75% tad-doża li tingħata titneħħa flippurgar, u l-bqija fl-awrina.
English: 6.5 Nature and composition of immediate packaging
Maltese: 6.1 Lista ta' sustanzi mhux attivi
English: Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours.
Maltese: Meloxicam huwa kompletament assorbit wara l-għoti mill-ħalq u l-ogħla konċentrazzjonijiet filplażma jinkisbu wara madwar 4.5 sigħat.
English: The suspension can be given using the Meloxoral measuring syringe provided in the package.
Maltese: Is-suspensjoni tista' tingħata jew permezz tas-siringa tal-kejl ta' Meloxoral ipprovduta fil-pakkett.
English: Meloxicam 1.5 mg.
Maltese: 1.5 mg
English: Sorbitol
Maltese: PARIR SABIEX
English: Marketing authorisation holder: Le Vet B.V
Maltese: Sid l-awtorizzazzjoni tal-kummerċ: Le Vet B.V
English: Evarrest fibrinogen / thrombin
Maltese: Evarrest fibrinoġen / thrombin
English: The full EPAR for Evarrest can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Evarrest
Maltese: Informazzjoni oħra dwar Evarrest
English: This summary was last updated in 09-2013.
Maltese: Settembru 2013.
English: This is a summary of the European public assessment report (EPAR) for Evarrest.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Evarrest .
English: Why is Evarrest approved?
Maltese: Għal xiex ġiet approvat Evarrest ?
English: In a study in patients undergoing abdominal, thoracic and pelvic surgeries, 84% of patients in the Evarrest group had their bleeding stopped within 4 minutes (50 out of 59) compared with 31% (10 out of 32) in the standard care group.
Maltese: Fi studju fuq pazjenti li kienu għaddejjin minn kirurġiji addominali, toraċiċi u pelviċi, 84% tal-pazjenti fil-grupp ta' Evarrest twaqqfitilhom il-fsada fi żmien 4 minuti (50 minn 59) meta mqabbla ma' 31% (10 minn 32) filgrupp tal-kura standard.
English: The active substances in Evarrest, fibrinogen and thrombin, are proteins extracted from the blood, which are involved in the natural clotting process.
Maltese: Is-sustanzi attivi f'Evarrest, fibrinoġen u thrombin, huma proteini li jiġu estratti mid-demm, li huma involuti fil-proċess naturali ta' tagħqid tad-demm.
English: What measures are being taken to ensure the safe and effective use of Evarrest?
Maltese: X'miżuri qegħdin jitteħdu biex jassiguraw użu sigur u effettiv ta' Evarrest?
English: Similar results were seen in a study in patients undergoing liver surgery: 83% of patients in the Evarrest group (33 out of 40) had their bleeding stopped within 4 minutes compared with 30% of the standard care group (13 out of 44).
Maltese: Riżultati simili dehru fi studju fuq pazjenti li kienu għaddejjin minn kirurġija tal-fwied: 83% tal-pazjenti fil-grupp ta' Evarrest (33 minn 40) twaqqfitilhom il-fsada fi żmien 4 minuti meta mqabbla ma' 30% fil-grupp tal-kura standard (13 minn 44).
English: A risk management plan has been developed to ensure that Evarrest is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jassigura li Evarrest jintuża bl-aktar mod sigur possibbli.
English: 98% of the patients in the Evarrest group (59 out of 60) had their bleeding stopped within 4 minutes (with no recurrence of bleeding during a 6-minute observation period) compared with 53% of patients in the Surgicel group (16 out of 30).
Maltese: Studju wieħed qabbel Evarrest ma' prodott ieħor, Surgicel, f'pazjenti li kienu għaddejjin minn kirurġiji addominali, toraċiċi u pelviċi. 98% tal-pazjenti fil-grupp ta' Evarrest (59 minn 60) twaqqfitilhom il-fsada fi żmien 4 minuti (bl-ebda rikorrenza ta' fsada matul perjodu ta' osservazzjoni ta' 6 minuti) meta mqabbla ma' 53% tal-pazjenti fil-grupp ta' Surgicel (16 minn 30).
English: Thrombin works by cutting fibrinogen up into smaller units called fibrin, which then stick together to form clots.
Maltese: Thrombin jaħdem billi jaqta' lil fibrinoġen f'unitajiet iżgħar magħrufa bħala fibrin, li mbagħad jeħlu flimkien biex jifformaw għoqiedi tad-demm.
English: What are the risks associated with Evarrest?
Maltese: X'inhuma r-riskji assoċjati ma' Evarrest ?
English: Evarrest is made of absorbable material that can be left in the patients after surgery.
Maltese: Evarrest huwa magħmul minn materjal li jixrob li jista' jitħalla fil-pazjenti wara l-kirurġija.
English: How is Evarrest used?
Maltese: Kif jaħdem Evarrest ?
English: The complications that arise in patients being treated with Evarrest are generally related to the surgical procedure and the underlying conditions, and include post-surgery bleeding and increased fibrinogen levels in the blood.
Maltese: Il-komplikazzjonijiet li jinqalgħu f'pazjenti li qed jirċievu kura b'Evarrest huma ġeneralment relatati mal-proċedura kirurġika u l-kundizzjonijiet sottostanti, u jinkludu fsada wara l-kirurġija u żieda fil-livelli ta' fibrinoġen fid-demm.
English: It is made of absorbable material coated on one side with two active substances, fibrinogen and thrombin, and is available as 10.2 cm x 10.2 cm patches.
Maltese: Huwa magħmul minn materjal li jixrob, miksi fuq naħa waħda b'żewġ sustanzi attivi, fibrinoġen u thrombin, u huwa disponibbli bħala gareż ta' 10.
English: One study compared Evarrest with another product, Surgicel, in patients undergoing abdominal, thoracic and pelvic surgeries.
Maltese: Evarrest huwa prodott kirurġiku li jintuża fuq adulti biex jgħin iwaqqaf il-fsada matul kirurġija meta metodi standard biex jikkontrollaw il-fsada mhumiex biżżejjed.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Evarrest was shown to be effective when used to stop bleeding in surgery and the product could be a suitable alternative to other products and techniques.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li Evarrest intwera li huwa effettiv meta jintuża biex iwaqqaf fsada waqt kirurġija u l-prodott jista' jkun alternattiva adegwata għal prodotti u tekniki oħra.
English: Evarrest has been shown in studies to be effective in helping to stop bleeding during surgeries, with most patients having their bleeding stopped within 4 minutes.
Maltese: Evarrest intwera fl-istudji li huwa effettiv biex iwaqqaf il-fsada matul kirurġiji, b'ħafna mill-pazjenti twaqqfitilhom il-fsada fi żmien 4 minuti.
English: The CHMP concluded that the benefits of Evarrest outweigh its risks and recommended that it be granted marketing authorisation.
Maltese: Is-CHMP ikkonkluda li l-benefiċċji ta' Evarrest jisbqu r-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Two studies compared Evarrest with commonly used surgical techniques considered to be standard care.
Maltese: Żewġ studji qabblu Evarrest ma' tekniki użati b'mod komuni meqjusin bħala kura standard.
English: The complications seen in studies with Evarrest were generally related the surgical procedure and the underlying conditions although there were cases of re-bleeding from the sites where Evarrest patches were used.
Maltese: Il-komplikazzjonijiet li dehru fi studji b'Evarrest kienu ġeneralment relatati malproċedura kirurġika u l-kundizzjonijiet sottostanti għalkemm kien hemm każijiet ta' tnixxija mill-ġdid mis-siti fejn kienu ntużaw il-garżi Evarrest.
English: The material is absorbed by the body in around 8 weeks.
Maltese: Il-materjal jiġi assorbit mill-ġisem wara madwar 8 ġimgħat.
English: Packaging Content Package sizeWithdrawal period
Maltese: Ippakkjar KontenutDaqs talpakkett
English: EU Number
Maltese: Numru ta' l-UE Isem
English: Route of administration
Maltese: Mod ta' Amministra-zzjoni
English: EU (MA) number
Maltese: Numru tal-UE Isem kummerċjali
English: MA (EU) Number (Invented) name
Maltese: Numru ta' l-EU Isem (ivvintat)
English: Concentrate for solution for infusion
Maltese: Konċentrat għal soluzzjoni għallinfużjoni
English: The full EPAR for Pixuvri can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Pixuvri.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Pixuvri.
English: Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin's B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients).
Maltese: Intwera li Pixuvri huwa ta' benefiċċju għal pazjenti b'limfoma taċ-ċelloli B mhux ta' Hodgkin aggressiva: 20% tal-pazjenti rreaġixxew bis-sħiħ għal Pixuvri (14 minn 70 pazjent) apparagun ma' 5.7% tal-pazjenti li ngħataw sustanzi oħrajn (4 minn 70 pazjent).
English: The most common side effects with Pixuvri (seen in more than 1 patient in 10) are neutropenia, leucopenia and lymphopenia (low levels of different types of white blood cells), thrombocytopenia (low levels of platelets in the blood), anaemia (low levels of red blood cells), nausea (feeling sick), vomiting, skin discolouration, hair loss, chromaturia (abnormal colouration of the urine) and asthenia (weakness).
Maltese: (li deher f'aktar minn pazjent wieħed minn għaxra) huma newtropenja, lewkopenja u limfopenja (livelli baxxi ta' tipi differenti ta' ċelloli bojod tad-demm), tromboċitopenija (livelli baxxi ta' plejtlits fid-demm), anemija (livelli baxxi ta' ċelloli ħomor tad-demm), nawżja (dardir), rimettar, tibdil fil-kulur tal-ġilda, telf ta' xagħar, kromaturja (kulur mhux normali talawrina) u astenja (dgħufija).
English: Pixuvri is a medicine that contains the active substance pixantrone.
Maltese: Pixuvri huwa mediċina li fiha s-sustanza attiva piksantronu.
English: The recommended dose is 50 mg/m2 given as an infusion into a vein over at least 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Maltese: Id-doża rakkomandata hija 50 mg/m2 mogħtija b'infużjoni f'vina tul mill-inqas 60 minuta fl-ewwel, fit-tmien u fil-15-il jum ta' ċiklu ta' 28 jum.
English: EPAR summary for the public pixantrone
Maltese: Sommarju tal-EPAR għall-pubbliku piksantronu
English: Pixuvri has been given ‘conditional approval'.
Maltese: Pixuvri ingħata ‘approvazzjoni kundizzjonali'.
English: Why has Pixuvri been approved?
Maltese: Għaliex ġie approvat Pixuvri?
English: Other information about Pixuvri
Maltese: Informazzjoni oħra dwar Pixuvri
English: The active substance in Pixuvri, pixantrone, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anthracyclines'.
Maltese: Is-sustanza attiva f'Pixuvri, il-piksantronu, hija mediċina ċitotossika (mediċina li toqtol iċ-ċelloli li jkunu qegħdin jiddividu, bħaċ-ċelloli tal-kanċer) li tappartieni lill-grupp ta' ‘antraċiklini'.
English: What is Pixuvri?
Maltese: Kif jintuża Pixuvri?
English: Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin's B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment.
Maltese: Pixuvri tqabbel ma' trattamenti oħrajn tal-kemjoterapija fi studju ewlieni wieħed fuq 140 adult b'limfoma taċ-ċelloli B mhux ta' Hodgkin aggressiva, li qabel kienu ngħataw mill-inqas żewġ trattamenti oħrajn, u li l-kanċer tagħhom kien reġa' feġġ jew ma kienx irreaġixxa għall-kura.
English: Pixuvri is used to treat adult patients with non-Hodgkin's B cell lymphoma.
Maltese: Il-mediċina tinkiseb biss b'riċetta ta' tabib.
English: However, the Committee noted that more data were needed on the benefits of Pixuvri in patients who have received previous treatment with rituximab (another medicine commonly used to treat lymphoma).
Maltese: Madankollu l-Kumitat innota li kien jenħtieġ aktar dejta dwar il-benefiċċji ta' Pixuvri fuq pazjenti li kienu ngħataw kura preċedenti birrituximab (mediċina oħra li normalment tintuża kontra l-limfoma).
English: The effects of Pixuvri were first tested in experimental models before being studied in humans.
Maltese: Qabelxejn l-effetti ta' Pixuvri ġew ittestjati fuq mudelli sperimentali qabel ma ġew studjati fil-bnedmin.
English: The company that makes Pixuvri will carry out a study to further investigate the effects of using Pixuvri in patients who had received prior treatment with rituximab.
Maltese: Il-kumpanija li tipproduċi Pixuvri ser tagħmel studju biex tinvestiga aktar fil-fond l-effetti tal-użu ta' Pixuvri fuq pazjenti li kienu ngħataw kura bir-rituximab.
English: For the full list of all side effects reported with Pixuvri, see the package leaflet.
Maltese: L-aktar effetti sekondarji komuni bl-użu ta' Pixuvri
English: It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins.
Maltese: Din taħdem billi tinterferixxi mad-DNA fiċ-ċellolli, u ma tħallihomx jagħmlu aktar kopji ta' DNA u proteini.
English: The CHMP concluded that patients with aggressive non-Hodgkin's B cell lymphoma had a better response to treatment with Pixuvri than other cancer treatments.
Maltese: Is-CHMP ikkonkluda li l-pazjenti b'limfoma taċ-ċelloli B mhux ta' Hodgkin aggressiva kellhom reazzjoni itjeb għall-kura b'Pixuvri milli għal kuri tal-kanċer oħrajn.
English: The CHMP also considered the seriousness of the disease and the lack of suitable alternative treatments for patients whose non-Hodgkin's B cell lymphoma has come back or has not responded to other chemotherapy treatments.
Maltese: Tqies li l-effetti sekondarji tal-mediċina idumu żmien qasir u huma maniġġabbli.
English: What is the risk associated with Pixuvri?
Maltese: Għal xiex jintuża Pixuvri?
English: EMA/635350/2015 EMEA/H/C/003905
Maltese: EMEA/H/C/003905
English: The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Pemetrexed medac is a ‘generic medicine'.
Maltese: Pemetrexed medac huwa ‘mediċina ġenerika'.
English: In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides' (the building blocks of DNA and RNA, the genetic material of cells).
Maltese: Fil-ġisem, pemetrexed jinbidel f'forma attiva li timblokka l-attività tal-enzimi li huma involuti fil-produzzjoni ta' ‘nukleotidi' (nucleotides - li fuqhom jinbnew DNA u RNA, il-materjal ġenetiku taċ-ċelloli).
English: Other information about Pemetrexed medac
Maltese: Aktar informazzjoni dwar Pemetrexed medac
English: • malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
Maltese: • mesoteljoma plewrika malinnja (kanċer tar-rita tal-pulmun, normalment ikkawżat minn esponiment għall-asbestos), meta jintuża flimkien ma' ċisplatin f'pazjenti li ma ngħatawx il-kemoterapija qabel u li l-kanċer li għandhom ma jistax jitneħħa b'intervent kirurġiku;
English: Pemetrexed medac contains the active substance pemetrexed.
Maltese: Pemetrexed medac fih is-sustanza attiva pemetrexed.
English: Pemetrexed medac is a cancer medicine used to treat two types of lung cancer:
Maltese: Pemetrexed medac huwa mediċina kontra l-kanċer li tintuża biex tikkura żewġ tipi ta' kanċers talpulmun:
English: This is a summary of the European public assessment report (EPAR) for Pemetrexed medac.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Pemetrexed medac.
English: The active substance in Pemetrexed medac, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Maltese: Is-sustanza attiva f'Pemetrexed medac, il-pemetrexed, hija mediċina ċitotossika (mediċina li toqtol iċċelloli li jkunu qed jiddividu ruħhom, bħaċ-ċelloli tal-kanċer) li jagħmlu parti mill-grupp tal‘antimetaboliti'.
English: Pemetrexed medac pemetrexed
Maltese: Kif jintuża Pemetrexed medac?
English: Why is Pemetrexed medac approved?
Maltese: Għaliex ġie approvat Pemetrexed medac?
English: Pemetrexed medac is available as a powder that is made up into a solution for infusion (drip) into a vein.
Maltese: Pemetrexed medac huwa disponibbli bħala trab li jsir f'soluzzjoni għal infużjoni (dripp) ġol-vina.
English: No additional studies were needed as Pemetrexed medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Maltese: L-ebda studju addizzjonali ma kien meħtieġ minħabba li Pemetrexed medac huwa mediċina ġenerika li tingħata permezz ta' infużjoni u li fiha l-istess sustanza attiva bħal tal-mediċina ta' referenza, Alimta.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed medac.
Maltese: Biex jitnaqqsu l-effetti sekondarji, il-pazjenti għandhom jieħdu kortikosterojde (tip ta' mediċina li tnaqqas l-infjammazzjoni) u aċidu foliku (tip ta' vitamina), u għandhom jirċievu injezzjonijiet ta' vitamina
English: A risk management plan has been developed to ensure that Pemetrexed medac is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Pemetrexed medac jintuża bl-aktar mod sigur possibbli.
English: Because Pemetrexed medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Pemetrexed medac huwa mediċina ġenerika, il-benefiċċji u r-riskji tiegħu huma meqjusin listess bħal dawk tal-mediċina ta' referenza.
English: When Pemetrexed medac is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Maltese: Meta Pemetrexed medac jingħata ma' ċisplatin, mediċina ‘antiemetika' (biex tipprevjeni r-remettar) u fluwidi (biex jipprevjenu ddiżidratazzjoni) għandhom jingħataw ukoll qabel jew wara d-doża ta' ċisplatin.
English: What are the benefits and risks of Pemetrexed medac?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Pemetrexed medac?
English: How has Pemetrexed medac been studied?
Maltese: Kif ġie studjat Pemetrexed medac?